


RealRate

## PHARMACEUTICAL 2018



## Brooklyn ImmunoTherapeutics Inc. Rank 81 of 349





## PHARMACEUTICAL 2018





## Brooklyn ImmunoTherapeutics Inc. Rank 81 of 349

The relative strengths and weaknesses of Brooklyn ImmunoTherapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Brooklyn ImmunoTherapeutics Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 583% points. The greatest weakness of Brooklyn ImmunoTherapeutics Inc. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 165% points.

The company's Economic Capital Ratio, given in the ranking table, is 14%, being 292% points above the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	9,638
Cost of Goods Sold	0
Intangible Assets	1,004
Liabilities, Current	10,747
Liabilities, Non-Current	52
Other Assets	2,250
Other Compr. Net Income	122
Other Expenses	7,155
Other Liabilities	235
Other Net Income	391
Property and Equipment	3,678
Research and Development	0
Revenues	21,274
Selling, General and Administrative Expense	15,587

Output Variable	Value in 1000 USD
Assets	16,570
Liabilities	11,034
Expenses	22,742
Stockholders Equity	5,536
Net Income	-1,077
Comprehensive Net Income	-1,016
Economic Capital Ratio	14%